Company intelligence / Profile preview
Neose Technologies, Inc.
Horsham, Pennsylvania, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Neose Technologies was a clinical-stage biopharmaceutical company focused on improving protein therapeutics using proprietary glycosylation technologies. Its lead program reached Phase 2 clinical trials for anemia. The company discontinued or divested its pipeline and sold substantially all assets to Novo Nordisk A/S and BioGeneriX AG in January 2009 for $43 million.[5][6]
- Therapeutic areas
- Infectious DiseasesImmunologyHematology
- Modalities
- BiosimilarsTherapeutic proteins (e.g., erythropoietin)Colony-stimulating factors[3]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Novo Nordisk A/SBioGeneriX AGprior strategic partnerships with other biopharma companies for co-development/licensing of glycosylation platforms[5][7]
Beyond the preview
Go deeper on Neose Technologies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neose Technologies, Inc..